Cosiporfin Sodium for Injection Photodynamic Therapy
A phase 2 trial of Gemcitabine and Cisplatin in biliary tract cancer, run by Shanghai Guangsheng Biopharmaceutical Co., Ltd, now recruiting.
Overview
Cosiporfin Sodium for Injection Photodynamic Therapy is a phase 2 interventional study registered as NCT07398339 by Shanghai Guangsheng Biopharmaceutical Co., Ltd, with 30 participants planned, started 2026-03-31 and due to reach its primary completion in 2027-03-31. Interventions recorded: Cosiporfin Sodium for injection, DVDMS, Gemcitabine Hydrochloride for Injection and Cisplatin for injection.
Similar pages
not linked directly; found by shared links- TrialAK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer
Shares Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Cisplatin and the tag pipeline.
- TrialPhase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Shares Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Cisplatin and the tag pipeline.
- TrialSHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer
Shares Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Cisplatin and the tag pipeline.
- TrialPhase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Shares Gemcitabine, Cisplatin and the tag pipeline.
- TrialDurvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
Shares Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Cisplatin and the tag pipeline.
- TrialA Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialProgrammed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC
Shares Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.